TNFSF11 and prostate carcinoma: It has been shown that Receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors improve the anti-metastatic activity of PD-1/PD-L1 inhibitors, resulting in subcutaneous growth suppression in mouse models of melanoma, prostate cancer, and colon cancer (27).